Literature DB >> 6192285

Histidinaemia. Part III: Impact; a prospective study.

J T Coulombe, B L Kammerer, H L Levy, B Z Hirsch, C R Scriver.   

Abstract

We describe a prospective study of histidinaemia. Probands and siblings (n = 21) with typical histidinaemia in 16 families were ascertained by newborn screening; diagnosis was confirmed by appropriate investigations in each subject; none had been treated by low histidine diet. The median age of subjects with histidinaemia was 9.5 y (mean 10.0, SD 3.5, range 6-18). Age-matched sib-pairs and their mothers were studied. IQ scores (Full Scale, Verbal and Performance Scores), Visual-Motor Integration Performance (Bender Gestalt and Koppitz scores), Wide Range Achievement Test (Reading and Mathematics), school performance, and psychological history were evaluated, as well as the medical history (pregnancy, delivery, neonatal, post-natal development). Findings were correlated with biochemical phenotype. CNS development in histidinaemic subjects (mean and distribution of scores) was normal; outlier values did not correlate with degree of histidinaemia. We can conclude that histidinaemia detected by newborn screening is a non-disadaptive phenotype.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192285     DOI: 10.1007/BF02338972

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  5 in total

1.  Routine newborn screening for histidinemia. Clinical and biochemical results.

Authors:  H L Levy; V E Shih; P M Madigan
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

2.  A simple indirect method of detecting the enzyme defect in histidinemia.

Authors:  H L Levy; H P Baden; V E Shih
Journal:  J Pediatr       Date:  1969-12       Impact factor: 4.406

3.  Evidence for delayed histidine transamination in neonates with histidinemia.

Authors:  H L Levy; P M Madigan; P Peneva
Journal:  Pediatrics       Date:  1971-01       Impact factor: 7.124

4.  Histidinaemia. Part III: Impact; a prospective study.

Authors:  J T Coulombe; B L Kammerer; H L Levy; B Z Hirsch; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

5.  Histidinaemia. Part II: Impact; a retrospective study.

Authors:  A Rosenmann; C R Scriver; C L Clow; H L Levy
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

  5 in total
  8 in total

Review 1.  Rare diseases and the assessment of intervention: what sorts of clinical trials can we use?

Authors:  B Wilcken
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

2.  The control of 5-hydroxytryptamine and dopamine synthesis in the brain: a theoretical approach.

Authors:  F A Hommes; J S Lee
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 3.  The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia.

Authors:  F A Hommes
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 4.  Clinical biochemistry of the neonatal period: immaturity, hypoxia, and metabolic disease.

Authors:  R A Harkness
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

5.  Histidinaemia. Part I: Reconciling retrospective and prospective findings.

Authors:  C R Scriver; H L Levy
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

6.  Histidinaemia. Part III: Impact; a prospective study.

Authors:  J T Coulombe; B L Kammerer; H L Levy; B Z Hirsch; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

7.  Histidinaemia. Part II: Impact; a retrospective study.

Authors:  A Rosenmann; C R Scriver; C L Clow; H L Levy
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

8.  Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice.

Authors:  Danique van Vliet; Vibeke M Bruinenberg; Priscila N Mazzola; Martijn H J R van Faassen; Pim de Blaauw; Ido P Kema; M Rebecca Heiner-Fokkema; Rogier D van Anholt; Eddy A van der Zee; Francjan J van Spronsen
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.